GB9614235D0 - Composition for enhanced uptake of polar drugs from mucosal surfaces - Google Patents

Composition for enhanced uptake of polar drugs from mucosal surfaces

Info

Publication number
GB9614235D0
GB9614235D0 GBGB9614235.1A GB9614235A GB9614235D0 GB 9614235 D0 GB9614235 D0 GB 9614235D0 GB 9614235 A GB9614235 A GB 9614235A GB 9614235 D0 GB9614235 D0 GB 9614235D0
Authority
GB
United Kingdom
Prior art keywords
composition
mucosal surfaces
enhanced uptake
polar drugs
polar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9614235.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Priority to GBGB9614235.1A priority Critical patent/GB9614235D0/en
Publication of GB9614235D0 publication Critical patent/GB9614235D0/en
Priority to JP10504949A priority patent/JP2000515503A/en
Priority to EP97930663A priority patent/EP0993305A2/en
Priority to GB9900050A priority patent/GB2330533B/en
Priority to CA002257563A priority patent/CA2257563A1/en
Priority to PCT/GB1997/001852 priority patent/WO1998001159A2/en
Priority to AU34539/97A priority patent/AU722724B2/en
Priority to NO985956A priority patent/NO985956D0/en
Priority to KR1019997000028A priority patent/KR20000023583A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
GBGB9614235.1A 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces Pending GB9614235D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
JP10504949A JP2000515503A (en) 1996-07-06 1997-07-07 Compositions for enhancing uptake of polar drugs from mucosal surfaces
EP97930663A EP0993305A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
GB9900050A GB2330533B (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
CA002257563A CA2257563A1 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
PCT/GB1997/001852 WO1998001159A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
AU34539/97A AU722724B2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
NO985956A NO985956D0 (en) 1996-07-06 1998-12-18 Mixture for improved uptake of polar drugs from mucosal surfaces
KR1019997000028A KR20000023583A (en) 1996-07-06 1999-01-06 composition for enhanced uptake of polar drugs from mucosal surfaces

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces

Publications (1)

Publication Number Publication Date
GB9614235D0 true GB9614235D0 (en) 1996-09-04

Family

ID=10796483

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9614235.1A Pending GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
GB9900050A Expired - Fee Related GB2330533B (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9900050A Expired - Fee Related GB2330533B (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Country Status (8)

Country Link
EP (1) EP0993305A2 (en)
JP (1) JP2000515503A (en)
KR (1) KR20000023583A (en)
AU (1) AU722724B2 (en)
CA (1) CA2257563A1 (en)
GB (2) GB9614235D0 (en)
NO (1) NO985956D0 (en)
WO (1) WO1998001159A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
CA2363123C (en) * 1999-02-22 2011-09-06 Kenneth Iain Cumming Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2004052405A1 (en) * 2002-12-11 2004-06-24 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
DE102004027924A1 (en) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Pharmaceutical form containing the active ingredient cholylsarcosine
ES2426445T3 (en) 2006-04-07 2013-10-23 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
KR20110007614A (en) 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 Compositions of gnrh related compounds and processes of preparation
PT4104848T (en) 2009-06-18 2024-01-04 Acerus Pharmaceuticals Usa Llc Safe desmopressin administration
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CN103476419A (en) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 Pharmaceutical compositions of iron for oral administration
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN108201531A (en) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
DE69427820T2 (en) * 1993-06-29 2001-11-08 Ferring B.V., Hoofdorp COMPOSITIONS FOR THE NASAL ADMINISTRATION OF DESMOPRESSIN
JPH11292787A (en) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd Transucosal preparation containing physiologically active peptide

Also Published As

Publication number Publication date
WO1998001159A2 (en) 1998-01-15
WO1998001159A3 (en) 1998-03-26
GB2330533B (en) 2000-10-25
NO985956L (en) 1998-12-18
KR20000023583A (en) 2000-04-25
GB2330533A (en) 1999-04-28
EP0993305A2 (en) 2000-04-19
AU3453997A (en) 1998-02-02
NO985956D0 (en) 1998-12-18
AU722724B2 (en) 2000-08-10
CA2257563A1 (en) 1998-01-15
JP2000515503A (en) 2000-11-21
GB9900050D0 (en) 1999-02-24

Similar Documents

Publication Publication Date Title
ZA987552B (en) Pharmaceutical composition for combination of piperidino-alkanol-decongestant
IL181059A0 (en) Pharmaceutical compositions containing isoflavones
GB9600426D0 (en) Compositions
EG24118A (en) Pharmaceutical compositions
IL127684A0 (en) Composition for appetite suppression
GB2330533B (en) Composition for enhanced uptake of polar drugs from mucosal surfaces
GB9616672D0 (en) Pharmaceutical compositions
GB9623205D0 (en) Novel pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
EP0885896A4 (en) Phospholipid composition
ZA979726B (en) Pharmaceutical compositions
KR100207900B1 (en) Dielectric ceramic composition
GB9606429D0 (en) Pharmaceutical compositions
SG50003A1 (en) Dielectric ceramics composition
PL337804A1 (en) Solubilised compositions of sertralin
GB9613457D0 (en) Pharmaceutical compositions
GB9623962D0 (en) Pharmaceutical composition
GB9618376D0 (en) Pharmaceutical compositions
GB9618964D0 (en) Oral composition
GB9610136D0 (en) Pharmaceutical compositions
HUP0003528A3 (en) Pharmaceutical compositions containing dihydropolyprenols
EP0906085A4 (en) Compositions
SI0941095T1 (en) Improved pharmaceutical compositions
GB9603942D0 (en) Pharmaceutical compositions
GB9606586D0 (en) Pharmaceutical compositions